Urinary Tract Infection News and Research

RSS

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

Mid-stream urine collection system: an interview with Giovanna Forte, Managing Director, Forte Medical

The mid-stream (MSU) is urine from the bladder, which carries the information clinicians need to accurately identify and diagnose a UTI, or in the case of antenatal patients, make sure all is well.

22 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Primary health care for patients with urinary tract infections can save nearly $4 billion in ER visits

Giving patients better access to primary health care could save nearly $4 billion a year in unnecessary emergency room visits for a single common complaint - urinary tract infections - according to a study by the Vattikuti Urology Institute at Henry Ford Hospital in Detroit.

7 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

Schizophrenia patients experiencing relapse are more likely to develop UTIs

Schizophrenia patients experiencing relapse are 29 times more likely than healthy individuals to have a urinary tract infection, researchers report.

4 Apr 2013

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

The U.S. Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.

30 Mar 2013

Patients at Michigan hospitals less likely to experience catheter-associated UTIs: Study

Patients at Michigan hospitals are less likely to experience a urinary tract infection caused by a catheter than at other hospitals in the country, according to a new study by the University of Michigan.

26 Mar 2013

Study: Flagellin plays a critical role in regulating host innate defences against UTIs

A new study by British scientists reveals that motile Escherichia coli isolates demonstrated significant activation of NF-κB signaling suggesting that flagellin plays a key role in up-regulating the host innate defences against urinary tract infections (UTIs).

15 Mar 2013

ST131 infection is more prevalent in LTCF residents and elderly population

Antibiotic-resistant Escherichia coli (E. coli) continues to proliferate, driven largely by expansion of a strain of E. coli know as sequence type ST131. A new study points to hospitals and long-term care facilities (LTCF) as settings in which this antibiotic-resistant strain is increasingly found.

14 Mar 2013

Mirabegron reduces frequency of incontinence episodes in phase III trial

In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.

5 Mar 2013

‘Traffic light’ guide for pediatric bacterial infection needs refining

Study results suggest that a “traffic light” system for categorizing the severity of infections in children fails to detect a substantial number of serious bacterial infections, particularly urinary tract infections.

26 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

General practitioners ‘may miss UTI in children’

Family doctors need to lower their threshold of suspicion for urinary tract infection in children, according to UK research.

18 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Certified IPs more likely to perceive evidence behind infection prevention practices

There is general agreement among hospital infection preventionists (IPs) with respect to which practices have weak or strong evidence supporting their use to prevent healthcare-associated infection, according to a new study published in the February issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

4 Feb 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

Potty training right from the birth can eliminate need for diapers

Western babies are potty trained later these days and need diapers until an average of three years of age. But even infants can be potty trained. A study by researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, followed 47 infants and their mothers in Vietnam - where potty training starts at birth and the need for diapers is usually eliminated by nine months of age.